<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<atom:link rel="self" href="http://podcast.peerviewpress.com/videohematologyus/podcast.xml" type="application/rss+xml" />
		<lastBuildDate>Wed, 08 Oct 2008 09:35:38 -0400</lastBuildDate>
		<title>PeerView CME/CE Video Podcast - Hematology</title>
		<itunes:author>PeerView Press</itunes:author>
		<link>http://www.peerviewpress.com</link>
		<generator>Podcast Maker v1.3.6 - http://www.lemonzdream.com/podcastmaker</generator>
		<description><![CDATA[PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.]]></description>
		<itunes:subtitle>Thought leader perspectives on current clinical advances in medicine</itunes:subtitle>
		<itunes:summary>PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.</itunes:summary>
		<language>en</language>
		<copyright>2007</copyright>
		<itunes:owner>
			<itunes:name>PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018</itunes:name>
			<itunes:email>webmaster@peerviewpress.com</itunes:email>
		</itunes:owner>
		<image>
			<url>http://podcast.peerviewpress.com/videohematologyus/hematology_video_podcast_album_art_QAAppr_160307_144.jpg</url>
			<title>PeerView CME/CE Video Podcast - Hematology</title>
			<link>http://www.peerviewpress.com</link>
			<width>144</width>
			<height>144</height>
		</image>
		<itunes:image href="http://podcast.peerviewpress.com/videohematologyus/hematology_video_podcast_album_art_QAAppr_160307.jpg" />
		<category>Science &amp; Medicine</category>
		<itunes:category text="Science &amp; Medicine" />
		<itunes:keywords>CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Hematology</itunes:keywords>
		<itunes:explicit>no</itunes:explicit>
		<item>
			<title>William Bensinger, MD - Therapeutic Options for Transplant- and Non-Transplant-Eligible Patients With Multiple Myeloma: A Clinical Update</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[In this activity, experts in hematology discuss latest clinical advances in the treatment of multiple myeloma.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file for full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this activity, experts in hematology discuss latest clinical advances in the treatment of multiple myeloma.</itunes:summary>
			<enclosure type="video/x-m4v" url="http://www.podtrac.com/pts/redirect.m4v?http://podcast.peerviewpress.com/videohematologyus/PA04421FCr392.m4v" length="40037835" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04421FCr392.m4v</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04421FCr392.m4v</guid>
			<pubDate>Thu, 04 Sep 2008 16:42:28 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:46:31</itunes:duration>
			<itunes:keywords>Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Therapeutic Options for Transplant- and Non-Transplant-Eligible Patients With Multiple Myeloma: A Clinical Update</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/videohematologyus/PA04421FCCMEInfo.pdf" length="296975" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04421FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04421FCCMEInfo.pdf</guid>
			<pubDate>Thu, 04 Sep 2008 16:41:28 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Multiple myeloma, melphalan, alkylators, thalidomide, bortezomib, lenalidomide, dexamethasone, thrombosis, proteasome inhibitor, carfilzomib</itunes:keywords>
		</item>
		<item>
			<title>Moshe Talpaz, MD - CML Controversial Issues: Debating the Use of Molecular Monitoring and Potential for Individualized Therapy</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[In this CME activity, experts provide an update on treatment resistance in CML. Definitions, prevalence, and mechanisms of resistance are reviewed, the benefits and limitations of using molecular monitoring in the clinical management of CML are assessed, strategies for selecting optimal targeted therapy to circumvent or overcome treatment resistance are debated, and the potential for tailoring tyrosine kinase therapy according to individual patient or disease characteristics, including BCR-ABL mutations, is discussed.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file or full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this CME activity, experts provide an update on treatment resistance in CML. Definitions, prevalence, and mechanisms of resistance are reviewed, the benefits and limitations of using molecular monitoring in the clinical management of CML are assessed, strategies for selecting optimal targeted therapy to circumvent or overcome treatment resistance are debated, and the potential for tailoring tyrosine kinase therapy according to individual patient or disease characteristics, including BCR-ABL mutations, is discussed.</itunes:summary>
			<enclosure type="video/x-m4v" url="http://www.podtrac.com/pts/redirect.m4v?http://podcast.peerviewpress.com/videohematologyus/PA04328FCe015.m4v" length="34089618" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04328FCe015.m4v</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04328FCe015.m4v</guid>
			<pubDate>Thu, 21 Aug 2008 09:53:41 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:41:40</itunes:duration>
			<itunes:keywords>CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - CML Controversial Issues: Debating the Use of Molecular Monitoring and Potential for Individualized Therapy</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/videohematologyus/PA04328FCCMEinfo.pdf" length="291630" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04328FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04328FCCMEinfo.pdf</guid>
			<pubDate>Thu, 21 Aug 2008 09:48:30 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>CML, chronic myelogenous leukemia, BCR-ABL, molecular monitoring, imatinib, dasatinib, resistance, TKI</itunes:keywords>
		</item>
		<item>
			<title>Guillermo Garcia-Manero, MD - Epigenetic Alterations as Targets of Therapy in Myelodysplastic Syndromes: Applying Science to Clinical Practice</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[In this program, an expert will discuss the concept of epigenetics and targets of epigenetic therapy in myelodysplastic syndromes (MDS). Recent data on efficacy and safety of novel DNA hypomethylating agents in the treatment of MDS are also reviewed, as well as the implications of these data for clinical practice and research. ]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file or full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this program, an expert will discuss the concept of epigenetics and targets of epigenetic therapy in myelodysplastic syndromes (MDS). Recent data on efficacy and safety of novel DNA hypomethylating agents in the treatment of MDS are also reviewed, as well as the implications of these data for clinical practice and research. </itunes:summary>
			<enclosure type="video/x-m4v" url="http://www.podtrac.com/pts/redirect.m4v?http://podcast.peerviewpress.com/videohematologyus/PA04356FCr372.m4v" length="28564793" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04356FCr372.m4v</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04356FCr372.m4v</guid>
			<pubDate>Mon, 12 May 2008 14:31:22 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:34:11</itunes:duration>
			<itunes:keywords>Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Info - Epigenetic Alterations as Targets of Therapy in Myelodysplastic Syndromes: Applying Science to Clinical Practice</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/videohematologyus/PA04356FCCMEinfo.pdf" length="247560" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04356FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04356FCCMEinfo.pdf</guid>
			<pubDate>Mon, 12 May 2008 14:30:24 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Epigenetics, DNA hypomethylating agents, 5-azacitidine, decitabine, growth-factor support, dosing regimens, combination regimens, toxicity, myelosuppression, thrombocytopenia, neutropenia</itunes:keywords>
		</item>
		<item>
			<title>Jamile M. Shammo, MD, FASCP - State of the Science in MDS: Update on Diagnosis, Evaluation, and Treatment</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[In this program, MDS experts present an update on disease classification and review new data on current and emerging treatment options.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file or full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this program, MDS experts present an update on disease classification and review new data on current and emerging treatment options.</itunes:summary>
			<enclosure type="video/x-m4v" url="http://www.podtrac.com/pts/redirect.m4v?http://podcast.peerviewpress.com/videohematologyus/PA04297FCr364.m4v" length="51279555" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04297FCr364.m4v</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04297FCr364.m4v</guid>
			<pubDate>Thu, 28 Feb 2008 16:31:07 -0500</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:37:54</itunes:duration>
			<itunes:keywords>acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - State of the Science in MDS: Update on Diagnosis, Evaluation, and Treatment</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/videohematologyus/PA04297FCCMEinfo.pdf" length="260021" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA04297FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA04297FCCMEinfo.pdf</guid>
			<pubDate>Thu, 28 Feb 2008 16:31:04 -0500</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>acute myeloid leukemia, AMG 531, AML, American Society of Hematology, anemia, ASH, azacitidine, clofarabine, cytarabine, cytogenetic testing, decitabine, deferasirox, deletion 5q, etanercept, FAB classification, homoharringtonine, IPSS, iron chelation</itunes:keywords>
		</item>
		<item>
			<title>Aryeh Shander, MD - Anemia Management and Blood Conservation in the Hospital Setting</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[In this activity, physicians who are expert in the management of anemia and the use of blood products discuss the efficacy and risks of RBC transfusion and alternative strategies for the management of anemia in the critically ill, including the use of erythropoiesis-stimulating agents.]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file or full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this activity, physicians who are expert in the management of anemia and the use of blood products discuss the efficacy and risks of RBC transfusion and alternative strategies for the management of anemia in the critically ill, including the use of erythropoiesis-stimulating agents.</itunes:summary>
			<enclosure type="video/x-m4v" url="http://www.podtrac.com/pts/redirect.m4v?http://podcast.peerviewpress.com/videohematologyus/PA03696FCr324.m4v" length="41254008" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA03696FCr324.m4v</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA03696FCr324.m4v</guid>
			<pubDate>Tue, 24 Jul 2007 09:50:40 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:36:54</itunes:duration>
			<itunes:keywords>Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Anemia Management and Blood Conservation in the Hospital Setting</title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/videohematologyus/PA03696FCCMEinfo.pdf" length="101040" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA03696FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA03696FCCMEinfo.pdf</guid>
			<pubDate>Tue, 24 Jul 2007 09:50:15 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>Anemia, Blood conservation, Critical care, Erythropoietin, Transfusion</itunes:keywords>
		</item>
		<item>
			<title>Jamile M. Shammo, MD, FASCP - Advances in Management of Myelodysplastic Syndrome </title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[In this CME activity, experts in the treatment of MDS present recent data on the efficacy and safety of novel agents used in the treatment of MDS. The current treatment options are also highlighted. ]]></description>
			<itunes:subtitle>Please be sure to view the accompanying (PDF) file or full CME/CE information.</itunes:subtitle>
			<itunes:summary>In this CME activity, experts in the treatment of MDS present recent data on the efficacy and safety of novel agents used in the treatment of MDS. The current treatment options are also highlighted. </itunes:summary>
			<enclosure type="video/x-m4v" url="http://www.podtrac.com/pts/redirect.m4v?http://podcast.peerviewpress.com/videohematologyus/PA03729FCs339.m4v" length="35520076" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA3729FCs339.m4v</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA03729FCs339.m4v</guid>
			<pubDate>Mon, 19 Mar 2007 17:01:55 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:31:27</itunes:duration>
			<itunes:keywords>MDS, myelodysplastic syndromes, AML, HSCT, allogeneic stem cell transplantation, GVHD, graft-versus-host disease, 5-azacytidine, decitabine, lenalidomide, iron chelation therapies, gemtuzumab ozogamicin, tipifarnib, clofarabine, lonafarnib, valproic acid</itunes:keywords>
		</item>
		<item>
			<title>CME/CE Information - Advances in Management of Myelodysplastic Syndrome </title>
			<itunes:author>PeerView Press</itunes:author>
			<description><![CDATA[Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.]]></description>
			<itunes:subtitle>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:subtitle>
			<itunes:summary>Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.</itunes:summary>
			<enclosure type="application/pdf" url="http://podcast.peerviewpress.com/videohematologyus/PA03729FCCMEinfo_2.pdf" length="98474" />
			<link>http://podcast.peerviewpress.com/videohematologyus/PA03729FCCMEinfo.pdf</link>
			<guid>http://podcast.peerviewpress.com/videohematologyus/PA03729FCCMEinfo_2.pdf</guid>
			<pubDate>Mon, 19 Mar 2007 17:00:47 -0400</pubDate>
			<category>Science &amp; Medicine</category>
			<itunes:explicit>no</itunes:explicit>
			<itunes:duration>00:00:00</itunes:duration>
			<itunes:keywords>MDS, myelodysplastic syndromes, AML, HSCT, allogeneic stem cell transplantation, GVHD, graft-versus-host disease, 5-azacytidine, decitabine, lenalidomide, iron chelation therapies, gemtuzumab ozogamicin, tipifarnib, clofarabine, lonafarnib, valproic acid</itunes:keywords>
		</item>
	</channel>
</rss>